Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
© Brubaker et al; licensee BioMed Central Ltd. 2006
Received: 02 November 2005
Accepted: 17 January 2006
Published: 17 January 2006
We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
After development of hormone-refractory metastatic disease, prostate cancer is incurable. The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. In this study we have examined the effects of a combination of zoledronic acid (ZOL), a new-generation bisphosphonate, and docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction when grown in the bone environment.
Intra-tibial injections of LuCaP 23.1 cells were used to generate tumors in the bone environment, and animals were treated with ZOL, docetaxel, or a combination of these. Effects on bone and tumor were evaluated by measurements of bone mineral density and histomorphometrical analysis.
ZOL decreased proliferation of LuCaP 23.1 in the bone environment, while docetaxel at a dose that effectively inhibited growth of subcutaneous tumors did not show any effects in the bone environment. The combination of the drugs significantly inhibited the growth of LuCaP 23.1 tumors in the bone.
In conclusion, the use of the osteolysis-inhibitory agent ZOL in combination with docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option.
Patients with advanced prostate cancer (CaP) suffer from the severe consequences of hormone-refractory disease and bone metastases. After development of metastatic hormone-refractory disease, CaP is incurable, with a median survival of 9 to 12 months. Given the near-certainty that processes associated with hormone-refractory CaP and bone metastasis contribute directly to morbidity (pain, bone fractures, bone marrow failure) of patients, treatment modalities that would eliminate the advanced disease, slow down progression, or improve the quality of life of patients with advanced CaP are of great interest. Hormonal therapy, radiotherapy, and chemotherapy do not cure hormone-refractory disease . Attacking the tumor cells by multiple mechanisms may prove to be much more effective in killing tumor cells; therefore combined chemotherapies are one of the most promising themes of today's clinical picture.
Zoledronic acid (ZOL) is one of the most potent of the new-generation bisphosphonates (BPs), compounds that inhibit bone lysis and have been used in the treatment of bone diseases and bone metastastatic disease [2–7], and stimulate apoptosis in cancer cells [8–10]. Effects of ZOL on tumor cells [11, 12], including prostate tumors [13–19], have been reported in the literature. In our previous in vivo studies we have shown that growth of subcutaneous CaP tumors was not inhibited by ZOL; however, growth of prostate cancer cells in the bone environment was significantly inhibited, but the tumors were not eradicated . We have also shown that the probable mechanisms of the effects of ZOL on tumor in bone are indirect, via its effects on bone cells . The value and potential of ZOL in treatment of patients with cancer-related bone disease were reviewed , and a large number of reports have recently documented the benefits of ZOL treatment in patients with advanced prostate cancer [20–31]. However, in parallel with our pre-clinical study, these published results suggest that BPs can slow progression of the disease, but a cure is not achieved. Therefore, combinations of BPs with other agents such as chemotherapeutic drugs to control tumor growth while regulating tumor-induced bone remodeling have appeared as a promising new treatment strategy.
Docetaxel, an inhibitor of tubulin depolymerization, has emerged as the most valuable chemotherapeutic treatment for advanced CaP. Phase II studies have shown decreased prostate specific antigen (PSA) levels and increased survival, with dosage amounts and regimens varying from 25–75 mg/m2 every 1 or 3 weeks [32–37]. However, the toxicity of this treatment is significant and complete cures are still not achieved .
The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. Therefore testing of combinations of BPs with other agents is of significant interest in the treatment of various cancers. Many of the initial studies of BPs in combination with chemotherapy were conducted on breast cancer or myeloma, where the bone lesions are highly osteolytic. Combinations of taxoids with BPs in vitro exhibited additive anti-tumor effects against invasion and adhesion  and induction of apoptosis in breast-cancer cells in vitro  and in vivo . Moreover, inclusion of BPs in standard chemotherapy has led to a sustained reduction in skeletal complications in breast-cancer patients [41–43]. In advanced CaP patients, ZOL in combination with docetaxel and low-dose estramustine phosphate was recently shown to decrease serum PSA and pain levels . Additionally, Vordos et al. reported that ZOL in combination with docetaxel decreased serum PSA by over 50% at 2 months in more than half of the patients . It has also been reported that the alendronate in combination with taxol is more effective in preventing development of bone metastases in a CaP animal model than either therapy independently .
In this study we used a combination of ZOL and docetaxel to evaluate changes in bone remodeling and tumor growth of an osteoblastic CaP xenograft, LuCaP 23.1.
All procedures were performed in compliance with the University of Washington Institutional Animal Care and Use Committee and NIH guidelines. LuCaP 23.1 is a PSA-producing human CaP xenograft , which is maintained subcutaneously (SC) in male athymic mice.
Intra-tibial tumors and docetaxel and zoledronic acid treatment
The right tibiae of forty male SCID mice (four-to-six-week-old, Fox Chase SCID mice, Charles River, Wilmington, MA) were injected with 2 × 105 LuCaP 23.1 cells as we have described previously . Briefly, 1–2 × 105 separated single LuCaP 23.1 cells in ~10–20 μl were injected into the proximal end of the tibia. After the procedures, animals received Buprenorphine as an analgesic (2 mg/kg body weight subcutaneously) until fully recovered (usually <24 hours). The tumor growth was monitored by measurements of serum prostate specific antigen (PSA) levels. The animals were randomized into 4 groups when tumors in bone were established (mean serum levels of PSA: 5–10 ng/ml). Groups were as follows: 1) a control group which received subcutaneous PBS injections; 2) a ZOL treatment group which received subcutaneous injections of ZOL twice a week (2.5 μg per injection, ~0.1 mg/kg, Novartis Pharma AG, Basel, Switzerland.); 3) a docetaxel treatment group which received intra-peritoneal injections of docetaxel every two weeks (400 μg per injection, 20 mg/kg, Aventis Pharmaceuticals Inc. Bridgewater, NJ); and 4) a group treated with a combination of ZOL + docetaxel which received subcutaneous injections of ZOL twice a week (2.5 μg per injection, ~0.1 mg/kg) and intra-peritoneal injections of docetaxel every two weeks (400 μg per injection, 20 mg/kg). Docetaxel was dissolved in ethanol and polysorbate 80. The final dilutions were prepared just before injection with 5% dextrose. Blood samples were collected every week for determination of serum PSA levels (IMx Total PSA assay, Abbott Laboratories, Abbott Park, IL). The mice were sacrificed 7 weeks after enrolment. Bone mineral density (BMD) was measured prior to sacrifice in the area adjacent to the growth plate (PIXImus Lunar densitometer, GE Healthcare, Waukesha, WI). Radiographs of the tibiae were taken prior to sacrifice. At sacrifice, five tumored tibiae from each group were embedded in methacrylate for bone histomorphometrical (BHM) analysis.
BHM analysis was performed on 6-μm longitudinal sections of calcified tibiae stained with Goldner stain in the middle of the tibia from five animals per group (Skeletech, Inc., Bothell, WA). The percentages of bone volume and tumor volume in the whole longitudinal section of tibiae (% BV/TV and % TuV/TV, respectively) were calculated. Detailed analysis of the trabecular bone, including determination of trabecular thickness in μm (Tb.Th.), trabecular number per mm (Tb.N.), trabecular separation in μm (Tb.Sp.), the ratio of osteoblast surface to bone surface as a percentage, the ratio of osteoclast number to bone surface as a percentage, osteoid surface to bone surface as a percentage (Os.S/BS) and osteoid thickness (Os.Th.), was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate, site of injection). Statistical analysis of the results was done using paired and unpaired Student's t tests as appropriate.
Effects of docetaxel on subcutaneous tumors
Six-to-eight-week-old male SCID mice were implanted with LuCaP 23.1 tumor fragments over the right scapular region. Tumor volume was measured twice weekly and calculated as L × H × W × 0.5236. After tumors reached 200 mm3 in size, animals were randomized into two groups. Group 1: animals received intra-peritoneal injections of PBS every two weeks; Group 2: animals received intra-peritoneal injections of 20 mg/kg docetaxel (Bristol-Myers Squibb, Princeton, NJ) every two weeks. Tumor growth was monitored twice weekly. Animals were sacrificed when the tumors reached ~1000 mm3 or when animals were becoming compromised.
Effects of osteoblastic CaP xenograft LuCaP 23.1 and ZOL and docetaxel on bone were further evaluated by measuring BMD. BMD of all tumored tibiae exhibited increased BMD in comparison to the non-tumored tibia (196–240% increases, p < 0.0001 for all, Figure 1F). These increases are due to the stimulation of osteoblastic activity by LuCaP 23.1 and, in groups 2 and 4, by administration of ZOL. However, no significant differences in BMD of tumored tibiae were observed among the four groups. The systemic effect of ZOL was demonstrated by low but statistically significant increases in the BMD of non-tumored tibiae in groups 2 and 4 compared to the normal tibiae of group 1 (group 1: 0.0496 ± 0.008 g/cm2, group 2: 0.0551 ± 0.001 g/cm2 (111%), and group 4: 0.0605 ± 0.001 g/cm2 (122%), p < 0.002 for both).
Results of histomorphometrical analysis of effects of the treatments on LuCaP 23.1 and bone
TB. N. (MM-1)
23.09 ± 9.34
30.62 ± 5.75
94.89 ± 31.75
6.06 ± 1.41
76.87 ± 20.90
7.24 ± 1.82
4.57 ± 0.29
15.97 ± 5.08
1.91 ± 0.35
36.51 ± 7.86
17.68 ± 6.79a
145.7 ± 31.64
5.08 ± 0.53
52.29 ± 13.51
3.96 ± 1.87
5.27 ± 0.45
8.46 ± 1.42a
0.83 ± 0.46a
29.46 ± 8.56
28.29 ± 11.18
81.53 ± 20.45
5.61 ± 0.90
100.6 ± 24.88
6.73 ± 1.84
5.21 ± 0.36
14.17 ± 4.36
1.19 ± 0.61
ZOL + DOC
40.38 ± 8.73a
11.13 ± 3.41a,b
118.5 ± 25.56
5.59 ± 0.51
61.48 ± 21.83
4.77 ± 1.01
4.98 ± 0.40
11.92 ± 5.90
0.77 ± 0.42a
CaP is an extremely heterogeneous disease, and to date treatment strategies with single agents have failed to cure advanced prostate cancer. New multimodality therapeutic combinations that target different pathways and produce pronounced and sustained clinical activity without severe toxicity are now considered the next frontier in treating advanced CaP. However, as expected, not all combinations will be superior to monotherapies; e.g., combinations of ZOL with Imatib mesylate (Gleevec)  or high doses of calcitriol and dexamethasone  are reported to have no beneficial effects beyond those of monotherapy.
ZOL has recently emerged as an effective treatment for inhibition of both normal and pathologic bone resorption, and this has had a major impact on the treatment of metastases to the bone. In advanced CaP, ZOL has been shown to significantly reduce bone pain and the incidence of skeletal complications . We have shown previously that ZOL inhibits growth of osteoblastic LuCaP 23.1 in the bone environment  and our new data show that lower amounts of ZOL (0.1 mg/kg) are also effective in suppression of LuCaP 23.1 growth in bone. In an earlier article we reported lowering of PSA levels as well as tumor volume by ZOL . The difference may be due to the lower dosage of ZOL used in the current study. Docetaxel-induced alterations in serum PSA levels followed tumor volume in animals harboring subcutaneous LuCaP 23.1, whereas ZOL treatment of LuCaP 23.1 in bone decreased tumor volume, but changes in serum PSA were not significant. We hypothesize that PSA may not reflect changes in the response of CaP bone metastases to ZOL treatment, and that regulation of tumor growth and of PSA expression are affected by different signaling pathways and to different extents in the bone environment.
Although the main action of ZOL is inhibition of osteoclastic bone resorption , there is some evidence suggesting direct anti-tumor effects of ZOL as well as a possible synergism with taxanes [9, 17, 48]. Taxanes have been shown to be effective against osteolytic experimental CaP metastases [49, 50] and docetaxel has recently been approved as a standard chemotherapy for advanced prostate cancer. In the present study, 20 mg/kg docetaxel administered every two weeks significantly inhibited the growth of subcutaneous LuCaP 23.1. However, the effectiveness of docetaxel as a single drug against growth of LuCaP 23.1 in the bone was insignificant. We speculate that the bioavailability of docetaxel may be reduced in the osteoblastic environment.
In the present study, administration of ZOL apparently had the effect of sensitizing the target cells to the effects of docetaxel. In fact in the presence of ZOL, the additional effect of docetaxel (~37% reduction in growth) was almost as great as that seen with ZOL compared with the control group (~42% reduction), although it should be noted that the comparison between ZOL and the ZOL/docetaxel combination failed to reach statistical significance because of modestly higher scatter within the ZOL-only group. Similar results were recently published by Kim et al. , who reported that ZOL and paclitaxel each inhibited tumor growth in models of experimental osteolytic bone metastases of CaP, and the inhibition was even more pronounced with the combination. Studies employing combinations of agents in androgen-independent preclinical models are also needed to extend these observations to a setting more similar to advanced CaP patients.
Our data show that the combination of ZOL and docetaxel is effective in inhibiting growth of osteoblastic metastases of prostate cancer. Because of the toxicity of chemotherapeutic agents such as docetaxel, it is important to insure that they are effective against disease as administered. Our data indicate that the single-agent effectiveness of docetaxel in the osteoblastic CaP environment may be limited, but ZOL may sensitize the target cells to the effects of docetaxel. These data support clinical evaluation of this combination in CaP patients.
prostate cancer, ZOL: zoledronic acid, DOC: docetaxel, BPs: bisphosphonates, SC: subcutaneously, BMD: bone mineral density, BHM: bone histomorphometry, BV/TV: bone volume in tissue volume, TuV/TV: tumor volume in tissue volume, Tb.Th.: trabecular thickness, Tb.N.: trabecular number, Tb.Sp.: trabecular separation, Ob.Pm./BPm.: osteoblast perimeter per bone perimeter, N.Oc./BS: osteoclast number per bone surface, Os.S/BS: osteoid surface per bone surface, Os.Th.: osteoid thickness
The authors would like to thank Dr. Michael Corey for editorial assistance and Ms. Janna Quinn for technical assistance. Zoledronic acid was kindly provided by Novartis Pharma AG, Basel, Switzerland, and Total PSA reagents by Abbot Laboratories. Studies were supported by a grant from Novartis Pharma AG.
- Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002, 52: 154-179.View ArticlePubMedGoogle Scholar
- Green JR: Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol. 2001, 28: 4-10. 10.1016/S0093-7754(01)90259-3.View ArticlePubMedGoogle Scholar
- Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001, 19: 558-567.PubMedGoogle Scholar
- Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991, 49: 407-415.View ArticlePubMedGoogle Scholar
- Fleisch H: Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. Semin Oncol. 2001, 28: 45-47. 10.1016/S0093-7754(01)90264-7.View ArticlePubMedGoogle Scholar
- Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988, 297: 772-773.View ArticlePubMedPubMed CentralGoogle Scholar
- Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10: 1478-1487.View ArticlePubMedGoogle Scholar
- Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.View ArticlePubMedGoogle Scholar
- Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.View ArticlePubMedPubMed CentralGoogle Scholar
- Mackie PS, Fisher JL, Zhou H, Choong PF: Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001, 84: 951-958. 10.1054/bjoc.2000.1679.View ArticlePubMedPubMed CentralGoogle Scholar
- Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001, 16: 2027-2034.View ArticlePubMedGoogle Scholar
- Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol. 2001, 28: 35-44. 10.1016/S0093-7754(01)90263-5.View ArticlePubMedGoogle Scholar
- Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61: 2602-2608.PubMedGoogle Scholar
- Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR: Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002, 62: 5564-5570.PubMedGoogle Scholar
- Corey E, Brown LG, Quinn JE, Poot M, M.P R, Higano CS, R.L. V: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003, 9: 295-306.PubMedGoogle Scholar
- Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M: Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate. 2004, 59: 120-131. 10.1002/pros.10363.View ArticlePubMedGoogle Scholar
- Coxon JP, Oades GM, Kirby RS, Colston KW: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004, 94: 164-170. 10.1111/j.1464-4096.2004.04831.x.View ArticlePubMedGoogle Scholar
- Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW: Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol. 2004, 46: 389-401. 10.1016/j.eururo.2004.04.022.View ArticlePubMedGoogle Scholar
- Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 2005, 8: 253-259. 10.1038/sj.pcan.4500815.View ArticlePubMedGoogle Scholar
- Berenson JR: Recommendations for zoledronic Acid treatment of patients with bone metastases. Oncologist. 2005, 10: 52-62. 10.1634/theoncologist.10-1-52.View ArticlePubMedGoogle Scholar
- Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA: Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004, 9: 687-695. 10.1634/theoncologist.9-6-687.View ArticlePubMedGoogle Scholar
- Price N: Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer. Clin Prostate Cancer. 2004, 3: 77-79.View ArticlePubMedGoogle Scholar
- Parker CC: Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004, 96: 1480-1481.View ArticlePubMedGoogle Scholar
- Altundag K, Altundag O, Morandi P, Gunduz M: High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004, 101: 1101-1102. 10.1002/cncr.20459.View ArticlePubMedGoogle Scholar
- Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la TA: Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2004, 94: 524-527. 10.1111/j.1464-4096.2004.04919.x.View ArticlePubMedGoogle Scholar
- Higano CS: Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004, 31: 331-352. 10.1016/j.ucl.2004.01.001.View ArticlePubMedGoogle Scholar
- Winquist E, Berry S: Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2004, 96: 1183-1184.View ArticlePubMedGoogle Scholar
- Saad F: Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer. 2005, 4: 31-37.View ArticlePubMedGoogle Scholar
- Parker CC: The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005, 95: 935-938. 10.1111/j.1464-410X.2005.05441.x.View ArticlePubMedGoogle Scholar
- Green JR: Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 2005, 44: 282-292.View ArticlePubMedGoogle Scholar
- Bertelli G, Heouaine A, Arena G, Botto A, Garrone O, Colantonio I, Occelli M, Fea E, Giubergia S, Merlano M: Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol. 2005, 1-6.Google Scholar
- Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J: A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology. 2004, 66: 281-287. 10.1159/000078328.View ArticlePubMedGoogle Scholar
- Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A: Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 2005, 65: 126-130. 10.1016/j.urology.2004.08.041.View ArticlePubMedGoogle Scholar
- Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP: A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003, 97: 537-544. 10.1002/cncr.11082.View ArticlePubMedGoogle Scholar
- Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY: Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2003, 63: 81-86. 10.1023/A:1023756707900.View ArticlePubMedGoogle Scholar
- Higano CS: Current status of treatment for patients with metastatic prostate cancer. Can J Urol. 2005, 12 Suppl 2: 38-41.PubMedGoogle Scholar
- Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999, 83: 263-269. 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054/bjoc.2001.1727.View ArticlePubMedPubMed CentralGoogle Scholar
- Stearns ME, Wang M: Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996, 16: 116-131.PubMedGoogle Scholar
- Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.View ArticlePubMedGoogle Scholar
- Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.View ArticlePubMedGoogle Scholar
- Lipton A: Bisphosphonates and breast carcinoma: present and future. Cancer. 2000, 88: 3033-3037. 10.1002/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH: Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res. 1996, 2: 1039-1048.PubMedGoogle Scholar
- Tiffany NM, Wersinger EM, Garzotto M, Beer TM: Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology. 2004, 63: 934-939. 10.1016/j.urology.2003.12.022.View ArticlePubMedGoogle Scholar
- Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer. 2002, 1: 145-152.View ArticlePubMedGoogle Scholar
- Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM: High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004, 24: 2897-2903.PubMedGoogle Scholar
- Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ: Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 2005, 65: 3707-3715. 10.1158/0008-5472.CAN-04-3601.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.